In the last trading session, 1.87 million ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares changed hands as the company’s beta touched 1.02. With the company’s per share price at $10.56 changed hands at -$0.27 or -2.49% during last session, the market valuation stood at $1.03B. SPRY’s last price was a discount, traded about -75.28% off its 52-week high of $18.51. The share price had its 52-week low at $7.55, which suggests the last value was 28.5% up since then.
Analysts gave the ARS Pharmaceuticals Inc (SPRY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRY as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ARS Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.12.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY was in red as seen at the end of in last trading. With action -10.28%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 0.09%, with the 5-day performance at -10.28% in the red. However, in the 30-day time frame, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is -25.00% down.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 52.0% from its current market value. According to analyst projections, SPRY’s forecast low is 18 with 30 as the target high. To hit the forecast high, the stock’s price needs a -184.09% plunge from its current level, while the stock would need to soar -70.45% for it to hit the projected low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Year-over-year growth is forecast to reach 60,052.67% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 15.46M. 5 analysts are of the opinion that ARS Pharmaceuticals Inc’s revenue for the current quarter will be 13.4M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -1.44%. The 2025 estimates are for ARS Pharmaceuticals Inc earnings to increase by 0.70%.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 1.86 shares estimated at $19.68 million under it, the former controlled 1.92% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.42% of the shares, roughly 1.38 shares worth around $14.6 million.
